Agency Licenses Both Toxicity and New Enslein Metabolism Modules
Applications of Physiologically Based Absorption Models in Drug Discovery and Development
This article describes the use of physiologically based models of intestinal drug absorption to guide the research and development of new drugs.
Simulations Plus Releases Software Update for Better Pharmaceutical Drug Design
ClassPharmer™ 4.5 Adds Powerful New Capabilities for Drug Molecule Design and Data Mining
Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man
UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus administration of UK-453,061 in male rat and infusion administration in dog...
Simulations Plus Software Most Accurate in Comparison Study
Pfizer Study Presented at International Society for the Study of Xenobiotics (ISSX) Meeting in Shanghai
Simulations Plus Releases Major GastroPlus™ Software Update
Version 6.0 Incorporates Major Upgrades to Several Modules, Additional User Conveniences
Simulation of Sublingual and Gastrointestinal Absorption of Nifedipine
To develop an integrated model for drug absorption from the oral cavity. The model simulates combined absorption of a drug from both the oral cavity and the gastrointestinal tract.
Simulation of Gabapentin Absorption and Bioavailability in Pediatric Patients
To fit an absorption-pharmacokinetic model for simulation of Gabapentin in adult and pediatric populations. The model will be able to describe the nonlinear dose dependence of absorption mediated by an amino…
GlaxoSmithKline Renews and Expands Global License for Simulations Plus Software
Company Adds Parsippany, NJ Site to Multi-year Agreement
Simulations Plus Reports Second Quarter and Six Months FY2008 Financial Results
Revenues Up 4.3%, and Earnings Up 9.0% for First 6 Months of FY2008
Simulations Plus Sets Date for Second Quarter Earnings Release and Conference Call
Conference Call to Be on Tuesday, April 15, at 4:15 PM EDT
U.S. FDA Renews and Expands GastroPlus(TM) Software License
Adds New ADMET Predictor(TM) Module
Simulations Plus’ Software Selected Application of Choice by Premier Pharmaceutical Company
Top 3 Company Adds Software Licenses to Multi-year Agreement
Population Pharmacokinetics of Bendamustine and Metabolites in Patients With Indolent Non-Hodgkin Lymphoma
Bendamustine is a bifunctional alkylating agent in development as monotherapy and in combination with other agents in the treatment of indolent non-Hodgkin lymphoma (NHL).
Model Feasibility Assessment as a Driver for Model-Based Drug Development
Complex pharmacometric analyses raise concerns about cost, time, and reliability of the modelbuilding process (MBP). The goal was to use a model feasibility assessment (MFA) process to improve the performance…
Simulations Plus Releases Major Upgrade to ADMET Predictor™ Software
Version 2.4 Adds Industry’s First Metabolism Kinetics Module for Key Enzymes
Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds
The goal of this study was to apply gastrointestinal simulation technology and integration of physiological parameters to predict biopharmaceutical drug classification.
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
What is already known about this subject. Vildagliptin is a new, potent, and selective inhibitor of DPP-4. The efficacy and safety of vildagliptin in type 2 diabetes has been...